Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial

被引:261
作者
Gheorghiade, Mihai
Rossi, Joseph S.
Cotts, William
Shin, David D.
Hellkamp, Anne S.
Pina, Ileana L.
Fonarow, Gregg C.
DeMarco, Teresa
Pauly, Daniel F.
Rogers, Joseph
DiSalvo, Thomas G.
Butler, Javed
Hare, Joshua M.
Francis, Gary S.
Stough, Wendy Gattis
O'Connor, Christopher M.
机构
[1] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Campbell Univ, Sch Pharm, Dept Clin Res, Res Triangle Pk, NC USA
[4] Univ Hosp Cleveland, Cleveland, OH 44106 USA
[5] Univ Calif Los Angeles, Los Angeles, CA 90024 USA
[6] Univ Calif San Francisco, San Francisco, CA 94143 USA
[7] Univ Florida, Shands Hosp, Gainesville, FL USA
[8] Massachusetts Gen Hosp, Boston, MA 02114 USA
[9] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[10] Johns Hopkins Univ, Baltimore, MD USA
[11] Cleveland Clin, Cleveland, OH 44106 USA
关键词
D O I
10.1001/archinte.167.18.1998
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Mild hyponatremia is relatively common in patients hospitalized with heart failure (HF). To our knowledge, the association of hyponatremia with outcomes has not been evaluated in the context of in-hospital clinical course including central hemodynamics and changes in serum sodium level. Methods: The ESCAPE trial (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) was a randomized, controlled study designed to evaluate the utility of a pulmonary artery catheter plus clinical assessment vs clinical assessment alone in guiding therapy in patients hospitalized with New York Heart Association class IV HF due to systolic dysfunction (left ventricular ejection fraction <30%). A Cox proportional hazards model with baseline serum sodium level as a continuous variable was used to examine the association of serum sodium level with 6-month postdischarge mortality, HF rehospitalization, and death or rehospitalization. A categorical analysis was also performed comparing persistent and corrected hyponatremia. Results: A total of 433 hospitalized patients with HF were enrolled in ESCAPE. Hyponatremia (serum sodium level <= 134 mEq/L) was present in 103 patients (23.8%). (To convert serum sodium to millimoles per liter, multiply by 1.0.) Of these, 71 had persistent hyponatremia (68.9%). Hyponatremia was associated with higher 6-month mortality after covariate adjustment (hazard ratio [HR] for each 3-mEq/L decrease in sodium level, 1.23; 95% confidence interval [CI], 1.05-1.43) (P=.01),. After controlling for baseline variables and clinical response, we found that patients with persistent hyponatremia had an increased risk of all-cause mortality (31% vs 16%; HR, 1.82) (P=.04), HF rehospitalization (62% vs 43%; HR, 1.52) (P=.03), and death or rehospitalization (73% vs 50%; HR, 1.54) (P=.01) compared with normonatremic patients. Conclusion: Persistent hyponatremia was an independent predictor of mortality, HF hospitalization, and death or rehospitalization despite clinical and hemodynamic improvements that were similar to those in patients without hyponatremia.
引用
收藏
页码:1998 / 2005
页数:8
相关论文
共 26 条
[1]   CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE [J].
CHIDSEY, CA ;
BRAUNWALD, E ;
MORROW, AG .
AMERICAN JOURNAL OF MEDICINE, 1965, 39 (03) :442-+
[2]   NEUROHUMORAL CONTROL MECHANISMS IN CONGESTIVE HEART-FAILURE [J].
COHN, JN ;
LEVINE, TB ;
FRANCIS, GS ;
GOLDSMITH, S .
AMERICAN HEART JOURNAL, 1981, 102 (03) :509-514
[3]   Short-term intravenous milrinone for acute exacerbation of chronic heart failure - A randomized controlled trial [J].
Cuffe, MS ;
Califf, RM ;
Adams, KF ;
Benza, R ;
Bourge, R ;
Colucci, WS ;
Massie, BM ;
O'Connor, CM ;
Pina, I ;
Quigg, R ;
Silver, MA ;
Georghiade, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (12) :1541-1547
[4]  
DZAU VJ, 1981, CIRCULATION, V63, P645, DOI 10.1161/01.CIR.63.3.645
[5]   PROSTAGLANDINS IN SEVERE CONGESTIVE HEART-FAILURE - RELATION TO ACTIVATION OF THE RENIN-ANGIOTENSIN SYSTEM AND HYPONATREMIA [J].
DZAU, VJ ;
PACKER, M ;
LILLY, LS ;
SWARTZ, SL ;
HOLLENBERG, NK ;
WILLIAMS, GH .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (06) :347-352
[6]   RENAL AND CIRCULATORY MECHANISMS IN CONGESTIVE-HEART-FAILURE [J].
DZAU, VJ .
KIDNEY INTERNATIONAL, 1987, 31 (06) :1402-1415
[7]   Risk stratification for in-hospital mortality in acutely decompensated heart failure - Classification and regression tree analysis [J].
Fonarow, GC ;
Adams, KF ;
Abraham, WT ;
Yancy, CW ;
Boscardin, WJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (05) :572-580
[8]   Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure - Results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial [J].
Gattis, WA ;
O'Connor, CM ;
Gallup, DS ;
Hasselblad, V ;
Gheorghiade, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (09) :1534-1541
[9]   Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome Study with Tolvaptan (EVEREST) [J].
Gheorghiade, M ;
Orlandi, C ;
Burnett, JC ;
Demets, D ;
Grinfeld, L ;
Maggioni, A ;
Swedberg, K ;
Udelson, JE ;
Zannad, F ;
Zimmer, C ;
Konstam, MA .
JOURNAL OF CARDIAC FAILURE, 2005, 11 (04) :260-269
[10]   Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure - A randomized controlled trial [J].
Gheorghiade, M ;
Gattis, WA ;
O'Connor, CM ;
Adams, KF ;
Elkayam, U ;
Barbagelata, A ;
Ghali, JK ;
Benza, RL ;
McGrew, FA ;
Klapholz, M ;
Ouyang, J ;
Orlandi, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (16) :1963-1971